Loading data
DRKNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.18 m USD | 16.61 m USD | 21.91 m USD | 6.08 m USD | 3.72 m USD |
| Cost of revenue | 8.55 m USD | 13.38 m USD | — | — | — |
| Gross profit | — | — | 5.96 m USD | 2.66 m USD | — |
| Research and development expense | — | 0 USD | 1.03 m USD | 605 k USD | 971 k USD |
| Operating profit | -22 m USD | -21.41 m USD | -30 m USD | -157.65 m USD | -19.72 m USD |
| Income tax expense | 2 k USD | 150 k USD | 13 k USD | 166 k USD | -15 k USD |
| Net income (reported basis) | -21.48 m USD | -9.47 m USD | -23.33 m USD | -192.91 m USD | -17.29 m USD |
| Net income attributable to common shareholders | — | -9.47 m USD | -23.41 m USD | -192.8 m USD | -17.82 m USD |
| Basic earnings per share | -7.37 USD/share | -4.78 USD/share | -1.93 USD/share | -20.36 USD/share | -0.58 USD/share |
| Diluted earnings per share | -7.37 USD/share | -4.78 USD/share | -1.93 USD/share | -20.36 USD/share | -0.58 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.